Your browser doesn't support javascript.
SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.
Mudd, Philip A; Minervina, Anastasia A; Pogorelyy, Mikhail V; Turner, Jackson S; Kim, Wooseob; Kalaidina, Elizaveta; Petersen, Jan; Schmitz, Aaron J; Lei, Tingting; Haile, Alem; Kirk, Allison M; Mettelman, Robert C; Crawford, Jeremy Chase; Nguyen, Thi H O; Rowntree, Louise C; Rosati, Elisa; Richards, Katherine A; Sant, Andrea J; Klebert, Michael K; Suessen, Teresa; Middleton, William D; Wolf, Joshua; Teefey, Sharlene A; O'Halloran, Jane A; Presti, Rachel M; Kedzierska, Katherine; Rossjohn, Jamie; Thomas, Paul G; Ellebedy, Ali H.
  • Mudd PA; Department of Emergency Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO 63110, USA. Electronic address: pmudd@wustl.edu.
  • Minervina AA; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Pogorelyy MV; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Turner JS; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Kim W; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Kalaidina E; Division of Allergy and Immunology, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Petersen J; Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia.
  • Schmitz AJ; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Lei T; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Haile A; Clinical Trials Unit, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Kirk AM; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Mettelman RC; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Crawford JC; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Nguyen THO; Department of Microbiology and Immunology, University of Melbourne, at Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3052, Australia.
  • Rowntree LC; Department of Microbiology and Immunology, University of Melbourne, at Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3052, Australia.
  • Rosati E; Institute of Clinical Molecular Biology, Christian-Albrecht University of Kiel, Kiel 24105, Germany.
  • Richards KA; David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.
  • Sant AJ; David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.
  • Klebert MK; Clinical Trials Unit, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Suessen T; Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Middleton WD; Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Wolf J; Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Teefey SA; Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • O'Halloran JA; Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Presti RM; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO 63110, USA; Clinical Trials Unit, Washington University School of Medicine, Saint Louis, MO 63110, USA; Division of Infectious Diseases, Department of Internal Medicine, Washington Univ
  • Kedzierska K; Department of Microbiology and Immunology, University of Melbourne, at Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3052, Australia.
  • Rossjohn J; Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria 3800, Australia; Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff CF14 4XN, UK.
  • Thomas PG; Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Electronic address: paul.thomas@stjude.org.
  • Ellebedy AH; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA; Andrew M. and Jane M. Bursky Center for Human Immunology and Im
Cell ; 185(4): 603-613.e15, 2022 02 17.
Article in English | MEDLINE | ID: covidwho-1588149
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
SARS-CoV-2 mRNA vaccines induce robust anti-spike (S) antibody and CD4+ T cell responses. It is not yet clear whether vaccine-induced follicular helper CD4+ T (TFH) cell responses contribute to this outstanding immunogenicity. Using fine-needle aspiration of draining axillary lymph nodes from individuals who received the BNT162b2 mRNA vaccine, we evaluated the T cell receptor sequences and phenotype of lymph node TFH. Mining of the responding TFH T cell receptor repertoire revealed a strikingly immunodominant HLA-DPB1∗04-restricted response to S167-180 in individuals with this allele, which is among the most common HLA alleles in humans. Paired blood and lymph node specimens show that while circulating S-specific TFH cells peak one week after the second immunization, S-specific TFH persist at nearly constant frequencies for at least six months. Collectively, our results underscore the key role that robust TFH cell responses play in establishing long-term immunity by this efficacious human vaccine.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Vaccination / T Follicular Helper Cells / SARS-CoV-2 / COVID-19 / MRNA Vaccines / Immunity Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Cell Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines, Synthetic / Vaccination / T Follicular Helper Cells / SARS-CoV-2 / COVID-19 / MRNA Vaccines / Immunity Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: Cell Year: 2022 Document Type: Article